Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:50:38.355Z.
Calculation as of: 2026-10-06T18:50:38.355Z.
Quote observation: 2026-10-06T18:42:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
BriaCell Therapeutics Corp.
Market Cap
$35.19M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$35.71M
EV/Sales Ratio
3.21x
TTM Avg
7.33x
3Y Avg
18.71x
5Y Avg
16.11x
Market Cap
$36.61M
EV/Sales Ratio
N/A
TTM Avg
59371.36x
3Y Avg
19906.10x
5Y Avg
11981.70x
Market Cap
$36.85M
EV/Sales Ratio
1.07x
TTM Avg
7.17x
3Y Avg
30.29x
5Y Avg
30.29x
Market Cap
$33.46M
EV/Sales Ratio
0.44x
TTM Avg
0.48x
3Y Avg
0.66x
5Y Avg
0.78x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $35.19M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.56M | 0.12x | 0.15x | 0.42x | 1.17x |
| EUDA Health Holdings Limited (EUDA)vs › | $35.71M | 3.21x | 7.33x | 18.71x | 16.11x |
| Elutia Inc (ELUT)vs › | $34.48M | 2.09x | 1.98x | 3.00x | 2.66x |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.42M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.31M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.61M | N/A | 59371.36x | 19906.10x | 11981.70x |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.85M | 1.07x | 7.17x | 30.29x | 30.29x |
| Accuray Incorporated (ARAY)vs › | $33.46M | 0.44x | 0.48x | 0.66x | 0.78x |
| HeartBeam, Inc. (BEAT)vs › | $33.35M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
